Newssos
A blood test called Stockholm3 detected 90% of aggressive prostate cancer cases in a clinical trial spanning more than 12,000 men, surpassing the traditional prostate-specific antigen test, which caught 74%, according to a study published in the Annals of Internal Medicine.
Researchers at the Karolinska Institutet in Sweden said the results suggest a potential shift in how prostate cancer screening is conducted, with Stockholm3 identifying significantly more dangerous cases without raising the rate of unnecessary follow-up procedures.
What the Trial Found The study followed men aged 50 to 74 — mostly Swedish or European — for two years, with all participants receiving both the PSA and Stockholm3 tests.
Of the 443 men diagnosed with aggressive prostate cancer during the follow-up period, Stockholm3 missed significantly fewer serious cases than PSA did.
Keep reading